Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 39 recruiting now full pipeline #105 of 28,707 conditions

Diabetes Mellitus, Type 1: full-pipeline trial registry

39 of 119 indexed Diabetes Mellitus, Type 1 trials are currently recruiting.

Corpus placement: #105 of 28,707 conditions by registered trial count.

119 US clinical trials · 39 currently recruiting · #105 of 28,707 conditions by registered trial count

Diabetes Mellitus, Type 1: 119 US clinical trials tracked, 39 recruiting.

Diabetes Mellitus, Type 1 is the subject of 119 registered US clinical trials on ClinicalTrials.gov, 39 of them currently open to new participants. 31 are in Phase 3-4 (later-stage) and 27 in Phase 1-2 (earlier-stage). The most active sponsor is Novo Nordisk A/S, running 11 of these trials.

Enrollment posture brief

Registry condition diabetes-mellitus-type-1

OPEN 39 | RECR 33% | LATE 31 | EARLY 27 | RANK #105 | SPON 11

Nearest open-share peer: Non-alcoholic Fatty Liver Disease (33% recruiting · 58 trials)

Triple Negative Breast Cance57.1%Healthy Participants35%Postoperative Pain34.7%Diabetes Mellitus, Type (th…33%Weight Loss26.1%
Open-enrollment share among volume-matched conditions near Diabetes Mellitus, Type 1

Diabetes Mellitus, Type 1 lists 39 open slots (33% of 119 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Diabetes Mellitus, Type 1 on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Diabetes Mellitus, Type 1 is recruiting below its size-band peers.

    39 of 119 indexed trials (32.8%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Diabetes Mellitus, Type 1 trials is spread across many organizations.

    Novo Nordisk A/S accounts for 11 of 119 trials (9.2%). 70 distinct sponsors appear on at least one study for this condition label.

  3. Typical Diabetes Mellitus, Type 1 enrolment sits around 73 participants.

    Median target enrolment is 73 among the 119 trials that report a genuine target (sentinel values excluded). 70 of those (58.8%) plan for fewer than 100 participants.

  4. Diabetes Mellitus, Type 1 research is mostly interventional.

    105 interventional and 14 observational studies make up this index (88.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 113Phase 214Phase 323Phase 48

Open and recent trials

119 total, page 1 of 3

RECRUITING 75,000 participants

TrialNet Pathway to Prevention of T1D

University of South Florida

NCT00097292

RECRUITING 50,000 participants

The T1D Exchange Registry

T1D Exchange, United States

NCT04629586

RECRUITING 4,000 participants

Genetics Of Autoimmunity In Type I Diabetes

Medical College of Wisconsin

NCT03648918

RECRUITING NA 1,178 participants

Best Practice Advisories to Reduce Inequities in Technology Use for People With Type 1 Diabetes

T1D Exchange, United States

NCT06931275

RECRUITING Phase 3 877 participants

A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes

Novo Nordisk A/S

NCT07076199

RECRUITING 500 participants

T1D Pregnancy & Me

Jaeb Center for Health Research

NCT06959316

RECRUITING 400 participants

Type 1 Diabetes Recurrence in Pancreas Transplants

University of Miami

NCT01047865

RECRUITING NA 324 participants

Closed Loop and Education for Hypoglycemia Awareness Restoration

Milton S. Hershey Medical Center

NCT06325202

RECRUITING Phase 3 300 participants

A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)

Eli Lilly and Company

NCT07222332

RECRUITING NA 200 participants

Behavioral Approaches to Reduce Diabetes Distress in Adults With Type 1 Diabetes: A Pragmatic SMART

University of North Carolina, Chapel Hill

NCT06405373

RECRUITING NA 160 participants

National Institute of Diabetes and Digestive Kidney Diseases* Share Plus: Continuous Glucose Monitoring with Data Sharing in Older Adults with Type 1 Diabetes* and Their Care Partners to Improve Time in Range and Reduce Diabetes Distress.

University of Utah

NCT05937321

RECRUITING NA 160 participants

Food Insecurity Reduction & Strategy Team

Stanford University

NCT06329375

RECRUITING Phase 2 150 participants

Repeat BCG Vaccinations For The Treatment Of Pediatric Type 1 Diabetes

Massachusetts General Hospital

NCT05180591

RECRUITING Phase 3 150 participants

A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults

Eli Lilly and Company

NCT07222137

RECRUITING Phase 3 150 participants

Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes

vTv Therapeutics

NCT06334133

RECRUITING Phase 3 150 participants

Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease

Alessandro Doria

NCT06217302

RECRUITING NA 140 participants

Hybrid Closed Loop Effectiveness Trial in Adults With Type 1 Diabetes

Boston Medical Center

NCT06236607

RECRUITING NA 128 participants

Diabetes Learning in Virtual Environments Just in Time for Community Reentry

Louise Reagan

NCT05286892

RECRUITING NA 120 participants

Device Use Reimagined Through Education And Mentorship

University of California, San Francisco

NCT06546930

RECRUITING NA 82 participants

Randomized Trial of Supplemental Synchronous and Asynchronous Telehealth to Improve Glycemic Control for Pediatric Patients With Type 1 Diabetes

University of California, Davis

NCT04428658

RECRUITING NA 80 participants

Game-based Pediatric Diabetes Education

Carnegie Mellon University

NCT06264258

RECRUITING Phase 3 60 participants

Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes

University of Colorado, Denver

NCT05819138

RECRUITING Phase 1 60 participants

Cellular Therapy for Type 1 Diabetes Using Mesenchymal Stem Cells

Medical University of South Carolina

NCT04061746

RECRUITING NA 58 participants

Efficacy and Safety of a Ketogenic Diet in Type 1 Diabetes

Washington University School of Medicine

NCT06503809

RECRUITING Phase 3 52 participants

A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes

Vertex Pharmaceuticals Incorporated

NCT04786262

RECRUITING NA 52 participants

Carbohydrate Beta Cell Function and Glucose Control in Children With Diabetes

Boston Children's Hospital

NCT05899166

RECRUITING NA 50 participants

Continuous Glucose Metrics in Patients With Gastroparesis in Type 1 or Type 2 Diabetes

Samita Garg

NCT06046833

RECRUITING 50 participants

Breaking Disparities in Access to Advanced Diabetes Technologies in Children With Type 1 Diabetes

Nemours Children's Clinic

NCT05849753

RECRUITING NA 40 participants

Starting Technology in At Risk Type 1 Diabetes Study

University of California, Los Angeles

NCT06453928

RECRUITING NA 30 participants

Effect of Inhaled Technosphere Insulin vs RAA Insulin on Exercise-Induced Hypoglycemia in Adults With T1D Using Automated Insulin Delivery

Jaeb Center for Health Research

NCT06880835

RECRUITING Phase 1 20 participants

Subcutaneous Pharmacokinetic Evaluation of Monomeric Insulin and Lyumjev in Adults With Type 1 Diabetes

Stanford University

NCT07090824

RECRUITING Phase 1 20 participants

Improving Islet Transplantation Outcomes With Gastrin for Type I Diabetes

City of Hope Medical Center

NCT03746769

RECRUITING NA 20 participants

Feasibility Study of Extended Wear Insulin Infusion Set Options During Home Use in People With Type 1 Diabetes

Tandem Diabetes Care

NCT07325461

RECRUITING NA 20 participants

Islet Transplantation in Patients With "Brittle" Type I Diabetes

University of Chicago

NCT01630850

RECRUITING Phase 1 18 participants

Safety and Efficacy of CELZ-201 in Patients With Recent Onset Type 1 Diabetes

Creative Medical Technology Holdings

NCT05626712

RECRUITING Early Phase 1 16 participants

Regulation of Brain Glucose Metabolism in Type 1 Diabetes

Yale University

NCT05317455

RECRUITING Early Phase 1 15 participants

CBTi for the Treatment of Insomnia in Type 1 Diabetes

University of Illinois at Chicago

NCT07091318

RECRUITING Phase 1 13 participants

A Study to Investigate Safety and Effectiveness of Porcine Pancreatic Cells (OPF-310) in Patients With Type 1 Diabetes Mellitus

Otsuka Pharmaceutical Factory

NCT06575426

RECRUITING Phase 2 10 participants

Islet Transplantation in Type 1 Diabetic Kidney Allograft

University of Chicago

NCT01241864

ACTIVE NOT RECRUITING Phase 2 227 participants

Phase 2b Trial Comparing HDV-Insulin Lispro to Insulin Lispro in Adults With Type 1 Diabetes Receiving Insulin Degludec

Diasome Pharmaceuticlas

NCT06238778

ACTIVE NOT RECRUITING 188 participants

Recent-Onset Type 1 Diabetes Extension Study Evaluating the Long-Term Safety of Teplizumab (PROTECT Extension)

Provention Bio, a Sanofi Company

NCT04598893

ACTIVE NOT RECRUITING NA 150 participants

Using Technology to Address Disparities and Promote Healthcare Equity in Type 1 Diabetes Registry

University of Chicago

NCT06899984

ACTIVE NOT RECRUITING NA 80 participants

Testing an Integrated Care Model Trial

Emory University

NCT06448429

ACTIVE NOT RECRUITING Phase 2 78 participants

Diabetes Autoimmunity Withdrawn In New Onset and In Established Patients

Tolerion

NCT03895437

ACTIVE NOT RECRUITING Phase 2 78 participants

Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NCT05743244

ACTIVE NOT RECRUITING Phase 4 60 participants

Metformin for Preeclampsia Prevention in Pregnant Women With Type 1 Diabetes Mellitus

Maisa N. Feghali, MD

NCT03570632

ACTIVE NOT RECRUITING NA 50 participants

Recurrent Hypoglycemia in Type 1 Diabetes (Aim 2)

University of Minnesota

NCT04387422

ACTIVE NOT RECRUITING 50 participants

MEtabolic and Renal Effects of AutoMAted Insulin Delivery Systems in Youth With Type 1 Diabetes Mellitus

University of Colorado, Denver

NCT03945747

ACTIVE NOT RECRUITING Phase 1 50 participants

Allogenic Islet Cell Transplantation

University of Chicago

NCT00160732

ACTIVE NOT RECRUITING NA 37 participants

Type 1 Together: A Peer Mentorship Program to Bolster Use of CGM

Nemours Children's Clinic

NCT06203067

Page 1 of 3 Next →

Phase Distribution

PhaseTrial count
Phase 1 13
Phase 2 14
Phase 3 23
Phase 4 8

Named interventions

Most-linked intervention names on Diabetes Mellitus, Type 1 records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
9 trials
insulin aspart Drug
7 trials
Insulin Lispro Drug
3 trials
insulin degludec Drug
3 trials
Insulin Glargine Drug
3 trials
Intraportal infusion of islet cells Procedure
3 trials
Human Insulin Inhalation Powder Drug
2 trials
Faster-acting insulin aspart Drug
2 trials

US sites by state

Facility locations filed on Diabetes Mellitus, Type 1 trials. A trial with sites in several states counts in each.

California 56 trials
Florida 39 trials
Colorado 34 trials
Georgia 24 trials
New York 21 trials
Illinois 20 trials
Texas 18 trials
Pennsylvania 17 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Diabetes Mellitus, Type 1 page

119 registered trials, 39 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 39 Diabetes Mellitus, Type 1 trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Novo Nordisk A/S sponsors the most Diabetes Mellitus, Type 1 trials on record, review their full trial history before evaluating a specific study. See Novo Nordisk A/S's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Diabetes Mellitus, Type 1 condition card totals 119 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.